Introduction
============

Though the incidence is relatively low, many industrialized countries prioritize meningococcal disease prevention due to its rapid onset, fulminant nature, high case fatality ratio, and long-term sequelae. The advent of conjugate vaccines against common meningococcal serogroups has proven a major advancement in controlling meningococcal disease. The UK was the first country to launch a national meningococcal conjugate vaccination program in 1999 using a serogroup C vaccine, resulting in a dramatic decline in serogroup C disease.[@b1-idr-4-161] In contrast to industrialized countries, the burden of meningococcal disease in the sub-Saharan African "meningitis belt" is large and frequent epidemics occur that are disruptive to the public health infrastructure.[@b2-idr-4-161] The development of a safe, effective, affordable conjugate vaccine against serogroup A meningococcal disease is a tremendous advance that has the potential to eliminate epidemic meningococcal disease as a public health concern in Africa.

Meningococcal conjugate vaccines were developed to overcome the limitations of polysaccharide vaccines. The defining characteristic of the protein--polysaccharide conjugate vaccine is the ability to induce a T-cell dependent immune response. The resulting immunologic benefits include priming for a memory response, antibody avidity maturation, development of protective antibodies in young children, and reduction of nasopharyngeal carriage. Conjugate meningococcal vaccines have the potential to protect unvaccinated age groups in a population through herd immunity. This review will focus on meningococcal conjugate vaccines and the impact of vaccination programs on meningococcal epidemiology.

Meningococcal disease
=====================

Meningococcal disease most commonly presents as a bloodstream infection or meningitis, with other localized infections such as pneumonia presenting less commonly. Bloodstream infection can occur with or without other localized infection. Meningococcemia, or fulminant bloodstream infection, occurs in approximately 20% of patients with bacteremia and results from rapid proliferation of meningococci in the blood. The overall case fatality ratio for meningococcal disease is approximately 10%--15%, and is as high as 25%--30% in patients with meningococcemia. Disease onset is often rapid, and death may occur within 24 hours in the absence of antimicrobial therapy. Globally, there are approximately 614,000 cases annually with the highest incidence in sub-Saharan Africa (10--25 per 100,000). The incidence in Canada, the US, and Europe varies substantially by country, ranging from 0.35 per 100,000 to three per 100,000 persons per year.[@b3-idr-4-161] Incidence also varies by age with infants at greatest risk and a second peak in incidence observed among adolescents in most industrialized countries.

*Neisseria meningitidis* is a Gram-negative, encapsulated diplococcus that exclusively infects humans. Thirteen distinct serogroups have been identified based on their capsular polysaccharide, with serogroups A, B, C, Y, and W-135 accounting for nearly all disease. Serogroup distribution varies globally, with serogroup A predominant in Africa, and serogroups B, C, and Y observed in Asia, Europe, and the Americas with variable frequency.[@b4-idr-4-161] Age-specific incidence also varies. In the US, serogroup B accounts for approximately 65% of infant disease, while serogroups C and Y cause the majority of disease in adolescents and serogroup Y predominates in the elderly.[@b5-idr-4-161]

*Neisseria meningitidis* is a transient commensal of the human nasopharynx. Acquisition of the organism and colonization of the nasopharynx is necessary for the development of disease, but not sufficient. In the majority of cases, carriage is an immunizing event, resulting in protective antibodies that prevent disease. The prevalence of carriage is highly variable. In industrialized countries, meningococcal carriage is observed in roughly 10% of the population overall, rising from 2% in children under 4 years to a peak of 24.5%--32% among 15- to 24-year-olds, then declining with increasing age.[@b6-idr-4-161],[@b7-idr-4-161] Though carriage prevalence can mirror the overall epidemiology of disease, the relationship between risk factors for disease and those associated with carriage is incompletely understood. Further, carriage prevalence does not predict the incidence of disease nor the occurrence or severity of outbreaks. Even in settings of outbreaks or in hyperendemic disease, nasopharyngeal carriage of disease-associated strains may be exceedingly rare. Serogroup and molecular diversity is greater among carried isolates than among invasive isolates.[@b8-idr-4-161]

Correlates of protection against meningococcal disease
======================================================

Because of the low incidence of meningococcal disease, prelicensure vaccine efficacy trials employing disease outcomes are not feasible. Meningococcal vaccines are evaluated and licensed based on evidence of an immune response in subjects receiving vaccine using serum bactericidal activity (SBA) as the immunologic correlate of protection. Goldschneider et al demonstrated that serum bactericidal antibody levels correlate with protection against meningococcal disease using human complement (hSBA). Titers of four to eight were shown to confer protection against disease and hSBA has since been considered the gold standard correlate of protection.[@b9-idr-4-161],[@b10-idr-4-161] In addition, SBA titers of ≥128 using baby rabbit complement (rSBA) have been shown to predict protection in humans.[@b11-idr-4-161]--[@b13-idr-4-161] Postlicensure studies in the UK validated these correlates of protection, and additionally proposed that titers between eight and 64 are also likely to be protective.[@b14-idr-4-161] While these correlates of protection have been evaluated for serogroup C disease, they have been generally used as correlates of protection for other serogroups. Controversy remains over the "best" complement source, and regulatory agencies have different requirements for testing in prelicensure trials.

Polysaccharide vaccines
=======================

Meningococcal polysaccharide vaccines have been in use since the 1970s. There are several combinations used globally, including bivalent (A,C), trivalent (A,C,W-135), and quadrivalent (A,C,Y, W-135) vaccines. The effectiveness of capsular polysaccharide vaccines has been demonstrated in military recruits, community outbreaks, and household contacts of affected individuals.[@b15-idr-4-161]--[@b18-idr-4-161] Serogroup A vaccines have also been used effectively during outbreaks in Africa.[@b19-idr-4-161]--[@b21-idr-4-161]

The immunologic characteristics of capsular polysaccharide vaccines limit their impact in preventive vaccination programs. The polysaccharide antigen is T-cell independent and stimulates antibody production in mature B-lymphocytes. Without a T-cell mediated response, there is no class switching, affinity maturation, or development of memory cells.[@b22-idr-4-161],[@b23-idr-4-161] Polysaccharide vaccines are not as effective in infants because infants lack the mature lymphocytes required for a robust immune response. Infants vaccinated between 7 and 12 months of age have an SBA concentration indistinguishable from unimmunized children by 24 months of age[@b24-idr-4-161] and effectiveness rapidly declines to 8% in children under 4 years of age.[@b25-idr-4-161] Moreover, revaccination does not induce a booster response and multiple doses may result in hypo-responsiveness to subsequent doses, although the clinical significance of this is unclear.[@b26-idr-4-161]--[@b28-idr-4-161] Finally, polysaccharide vaccines do not completely protect from acquisition of nasopharyngeal carriage and therefore they do not provide long-term herd immunity.[@b29-idr-4-161],[@b30-idr-4-161]

Conjugate vaccines
==================

Conjugation of capsular polysaccharides to a protein carrier results in a T-dependent immune response. These carrier proteins are presented by polysaccharide specific B-cells to helper T-cells, enhancing production of plasma cells and memory B-cells. The result is a more robust immune response compared with polysaccharide vaccines, including greater antibody persistence, greater avidity, and long-term immunologic memory.[@b31-idr-4-161] Conjugate vaccines to respiratory bacterial pathogens are immunogenic in infants, and protect against acquisition of nasopharyngeal carriage. Several formulations of meningococcal conjugate vaccines are currently available ([Table 1](#t1-idr-4-161){ref-type="table"}). Their composition varies greatly and differences in capsular serogroup used, modification of the capsular antigen, type of carrier protein used, and the method of conjugation all can affect the characteristics of the immune response and therefore the effectiveness of the vaccine. Vaccine effectiveness is also dependent on the targeted vaccination group and the dosing schedule. Immune responses and waning immunity are age dependent, with young infants and children requiring more doses and demonstrating more rapid decline in antibody levels compared to older children and adolescents.[@b31-idr-4-161]

The contribution of the memory response to duration of protection of meningococcal vaccines is unclear. Studies suggest that circulating antibody is needed for protection from meningococcal vaccines due to the rapid onset of disease; therefore antibody persistence studies can be used to estimate duration of protection of meningococcal vaccines.[@b32-idr-4-161] Because vaccine licensure studies rely on short-term immunogenicity as the evaluated outcome, disease surveillance and postlicensure evaluations of meningococcal vaccination programs are critical for determining the most effective vaccination strategies.

Immunogenicity of monovalent serogroup C vaccines
=================================================

Meningococcal serogroup C (MCC) vaccines were introduced in the UK in 1999 in response to high rates of serogroup C disease caused by a virulent clone ([Table 1](#t1-idr-4-161){ref-type="table"}).[@b1-idr-4-161] The safety and immunogenicity of the three different MCC vaccines in children and adults have been demonstrated in several studies, and there are no substantial differences in effectiveness between the vaccine types.[@b33-idr-4-161]--[@b40-idr-4-161] Ninety-eight percent of infants develop rSBA titers ≥8, the putative correlate of protection, following a three-dose series at 2, 3, and 4 months of age.[@b33-idr-4-161],[@b36-idr-4-161]--[@b38-idr-4-161],[@b41-idr-4-161] Similar immune responses are seen following a two-dose series at 3 and 5 months as well as a single dose in older children and adults.[@b42-idr-4-161]--[@b44-idr-4-161],[@b47-idr-4-161]

Antibody persistence has been followed closely after MCC vaccination in the UK, and waning immunity is demonstrated, especially in infants and young children. In the absence of a booster dose, only 8%--12% of children completing a three-dose series in infancy had rSBA titers ≥8 at age 4 years.[@b45-idr-4-161] Among 250 children primed at ages ranging from 2 months to 6 years, only 25% (95% confidence interval \[CI\]: 20%--30%) had protective rSBA titers ≥8 at 1 year.[@b46-idr-4-161] Among children who received a single dose of MCC vaccine at age 2 years, 37% had a titer ≥8, 2 years later.[@b48-idr-4-161] Even following a booster dose in the second year of life only 23%--43% of children maintained protective SBA titers 2 years later.[@b49-idr-4-161] Waning immunity among adolescents vaccinated with MCC is much less pronounced. In two studies of adolescents vaccinated at age 10 years, 62%--75% of adolescents vaccinated maintained protective hSBA titers ≥8 3--6 years following vaccination.[@b47-idr-4-161],[@b50-idr-4-161] In a third study, Snape et al found that 5-year postvaccination GMT titers were significantly greater in children vaccinated after age 10 years than those vaccinated at age 6--10 years.[@b51-idr-4-161] These studies suggest that immune maturation may play an important role in duration of protection.

Immunogenicity of quadrivalent serogroup A, C, Y, W-135 vaccines
================================================================

Two quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccines are licensed in the US ([Table 1](#t1-idr-4-161){ref-type="table"}). While these vaccines are often recommended and used for protection against serogroup A in travelers, the US is the only country that employs a routine program of immunization due to the proportion of meningococcal disease caused by serogroup Y.

Prelicensure trials for MenACWY~D~ demonstrated the safety and immunologic noninferiority to quadrivalent polysaccharide vaccine. At 28 days after a single dose, a similar high proportion of 11- to 18-year-old subjects achieved at least a four-fold rise in rSBA titers, and the proportion achieving rSBA of ≥128 was \>98% for all serogroups for both vaccines.[@b52-idr-4-161] Comparable results were demonstrated for adults ages 18 through 55 years, with \>97% rSBA ≥128 for all serogroups for both vaccines.[@b53-idr-4-161] High rates of protective rSBA titers ≥128 were also demonstrated in children aged 2--10 years with levels varying depending on the serogroup (81% for serogroup C to 97% for serogroup A).[@b54-idr-4-161]

MenACWY~CRM~ is a second quadrivalent vaccine using diphtheria cross-reactive protein as the carrier protein. A randomized controlled trial conducted among persons aged 11--18 years demonstrated noninferiority of MenACWY~CRM~ compared to MenACWY~D~ for all four serogroups. The proportions of subjects with rSBA seroresponse were statistically higher for serogroups A, W-135, and Y in the MenACWY~CRM~ group, compared with the MenACWY~D~ group.[@b55-idr-4-161] Other randomized controlled trials among persons aged 19--55 years and children aged 2--10 years demonstrated similar results.[@b56-idr-4-161],[@b57-idr-4-161] While statistically significant, these differences were small and assays have not been standardized, making direct comparisons somewhat difficult. The clinical relevance of the higher postvaccination immune responses is not known.

The duration of protection following vaccination with quadrivalent meningococcal conjugate vaccines remains an important subject of evaluation. Persistence of protective levels of antibodies 3 years postvaccination as well as immunologic priming have been demonstrated in adolescent recipients of MenACWY~D~; however, studies are inconsistent and all demonstrate significant declines in antibody levels over 3 years.[@b52-idr-4-161],[@b58-idr-4-161] For serogroup C, geometric mean titers (GMT) declines as much as 90% over 3 years and the proportion of adolescents with protective antibodies is as low as 30%--54%.[@b52-idr-4-161],[@b59-idr-4-161] The proportion of 2-year-olds with hSBA titers ≥4 6 months following vaccination was approximately 50% for serogroups C, Y, and W-135.[@b60-idr-4-161],[@b61-idr-4-161] Similar decline in the duration of protection is seen with MenACWY~CRM~. At 22 months postvaccination, 34% (serogroup A) to 84% (Serogroup W-135) had hSBA ≥8.[@b59-idr-4-161] Concerns of waning immunity prompted the US to recommend a booster dose as part of its adolescent immunization program.[@b62-idr-4-161]

Immunogenicity of monovalent serogroup A conjugate vaccine
==========================================================

Epidemic meningococcal disease remains a devastating public health problem in the sub-Saharan African meningitis belt, stretching across the Sahel from Senegal to Ethiopia. Annual incidence averages from 25--100 cases per 100,000 persons, and can exceed 1000 cases per 100,000 during peak epidemic years. Serogroup A is the predominant disease- and outbreak-associated serogroup in the region.[@b3-idr-4-161] Polysaccharide vaccines have been used with some success for many years to limit the extent of disease in outbreak settings. Until recently, fiscal and logistical considerations prevented the development and large-scale introduction of a conjugate vaccine as part of a preventive vaccination program. In 2010, MenAfriVac, a new meningococcal A -- tetanus toxoid conjugate vaccine was licensed for persons aged 1--29 years old and prequalified by the World Health Organization for use in Africa. Since September 2010, over 20 million people have been vaccinated in Burkina Faso, Mali, and Niger. This is the first large-scale introduction of a meningococcal conjugate vaccine in Africa. At a price of US\$0.40 per dose, the current strategy of mass vaccination of all 1--29 year olds is within reach of even the poorest countries of the region. Subsequent vaccination of infants, if necessary, will require further mobilization of support from additional donors.[@b63-idr-4-161]

In a published prelicensure trial of 105 adults aged 18--35 years who received one dose of MenA vaccine, 100% and 92% of subjects had protective titers by 4 weeks postvaccination by rSBA and hSBA, respectively. Greater than four-fold increases in antibody titers were seen in 83% and 87% of subjects, with demonstrated antibody persistence at 1 year. Using rSBA assays, 100% of subjects with a four-fold rise in titers maintained this response at 1 year postvaccination. Protective rSBA titers ≥8 as well as MenA IgG \> 2 μg/mL 1 year postvaccination were also seen in 100% of patients.[@b64-idr-4-161],[@b65-idr-4-161] Data from these trials are similar to that seen in other meningococcal conjugate vaccines. Continued effectiveness studies in the field are ongoing and necessary to evaluate the long-term effect of this vaccine on epidemic meningococcal disease.

Immunologic memory and booster response after meningococcal conjugate vaccination
=================================================================================

Conjugate vaccines elicit immunologic memory, but memory may not play as important a role in protection against meningococcal disease compared to *Haemophilus influenza* and *Strepcococcus pneumoniae*. Meningococcal conjugate vaccines prime the immune system and immunologic memory persists even in the absence of detectable bactericidal antibodies. In a study of 4-year-olds in whom postconjugate vaccination titers had declined to prevaccination levels, boosting with meningococcal polysaccharide vaccine resulted in a 1000-fold increase in geometric mean titers and geometric mean avidity index was 1.33-fold higher 1 month following the vaccine. High GMTs are achieved after boosting following a single primary dose of MCC at 12 months of age.[@b37-idr-4-161],[@b38-idr-4-161],[@b43-idr-4-161],[@b46-idr-4-161],[@b66-idr-4-161]--[@b70-idr-4-161]

A strong association has been noted between MCC-specific antibody levels and the number of memory B cells measured after immunization. This level correlates with antibody persistence at 1 year, suggesting the importance of persistence of functional antibody in long-term humoral immunity.[@b71-idr-4-161] However, additional studies of the kinetics of antibody responses following boosting show that it takes up to 10 days to achieve protective SBA titers ≥8 in adults.[@b72-idr-4-161] If antibody presence wanes, this lag may not be rapid enough to protect against infection with *N. meningitidis*, considering the rapid onset of disease. Analyses of breakthrough cases following vaccination have found evidence of priming but low SBA activity. An anamnestic immune response is observed, but is hypothesized not to occur prior to development of invasive disease.[@b32-idr-4-161]

Meningococcal vaccine programs and vaccine effectiveness
========================================================

Since routine meningococcal vaccination was introduced in the UK in 1999, vaccination programs have expanded across Europe, Australia, and North America ([Table 2](#t2-idr-4-161){ref-type="table"}).[@b73-idr-4-161]--[@b79-idr-4-161] These programs have been implemented using various schedules and target age groups.[@b1-idr-4-161],[@b77-idr-4-161],[@b78-idr-4-161],[@b80-idr-4-161],[@b81-idr-4-161] In general, vaccine effectiveness estimates have paralleled immunogenicity data, but the observed public health impact of these programs is likely a combination of the vaccines used, the target age groups, and the recommended schedule. While some countries have implemented routine recommendations for a specific age group, others have implemented catch-up campaigns in addition to routine recommendations, more rapidly achieving high vaccine coverage and population protection. Differences in circulating strain diversity may also contribute to varying vaccine effectiveness, and postlicensure studies have demonstrated the importance of reduction in carriage and herd immunity.[@b84-idr-4-161]--[@b88-idr-4-161]

In the UK, vaccine effectiveness in adolescents (93%) was sustained up to 4 years after the catch-up vaccination. While effectiveness was high (83%) in those receiving catch-up immunization after 5 months of age, it was lower among those vaccinated in infancy (66%).[@b82-idr-4-161],[@b83-idr-4-161] In Spain, vaccine effectiveness greater than 1 year postvaccination was 78% among those vaccinated in infancy, but 94% among children ages 7 months--5 years at vaccination.[@b84-idr-4-161],[@b85-idr-4-161] VE studies in United States are ongoing, but initial estimates suggest vaccine effectiveness wanes to 50%--60% 2--5 years after vaccination.[@b87-idr-4-161]

Conjugate vaccine programs have potential to provide indirect protection through herd immunity. Two years after introduction of MCC vaccine in the UK, serogroup C carriage was reduced by 67%.[@b86-idr-4-161] Attack rates among unvaccinated children in the UK also declined by 67% in the 4 years following vaccine introduction. Between 1998 and 2009, the incidence of serogroup C disease in persons over 25 years dropped from 0.55 per 100,000 persons to 0.02 per 100,000 persons; and the number of cases in infants under 3 months of age dropped from 13 in 1998 to one in 2009.[@b88-idr-4-161] These effects were seen despite a declining seroprevalence of protective antibodies among vaccination cohorts as early as 18 months after the last scheduled dose of vaccine, suggesting sustained protection due to herd immunity despite absence of protective antibodies in individuals.[@b89-idr-4-161] Additional suggestions of herd immunity come from Ontario, where a 16% reduction per year in serogroup C disease occurred among persons ≥20 years of age from 2000--2006 following introduction of an MCC vaccination program in adolescents and infants in 2001.[@b90-idr-4-161] Herd immunity has not been demonstrated in the United States, where coverage with quadrivalent meningococcal vaccine among adolescents has increased slowly in the 5 years since introduction.

Future directions
=================

Meningococcal conjugate vaccination programs in the meningitis belt are just beginning and have potential to eliminate epidemic serogroup A meningococcal disease as a public health concern in the region. In 2010, Burkina Faso, Mali, and Niger implemented large-scale vaccination campaigns country or district wide, vaccinating all persons ages 1--29 years.[@b63-idr-4-161] Programs of mass vaccination campaigns followed by routine infant or early childhood vaccination were modeled on the successful experience in the UK. As the vaccine is implemented, case-based, laboratory-confirmed surveillance is crucial to evaluating the early long-term impact on both disease and the circulating strains. Special studies are also needed to understand impact on carriage and vaccine effectiveness.

To maximize impact at an acceptable cost is the challenge for meningococcal vaccination programs in industrialized countries. The Advisory Committee on Immunization Practices in the US recently recommended adding a booster dose of MenACWY for all 16-year-olds, 5 years after their initial dose, because early data suggested clinically relevant waning immunity. In contrast, reductions in serogroup C disease persist over 10 years after the catch-up campaigns in the UK. There is no evidence for strain replacement in England and Wales following implementation of a nationwide conjugate vaccine program.[@b91-idr-4-161] Nonetheless, there is evidence of increased genetic diversity in strains causing invasive disease in the UK and ongoing surveillance is necessary.[@b92-idr-4-161] Countries continue to monitor for increases in disease caused by serogroups not in their current vaccination program, and meningococcal vaccination programs will surely adapt to changes in disease patterns in the future.
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###### 

Meningococcal conjugate vaccine products[^1^](#tfn1-idr-4-161){ref-type="table-fn"}

  **Vaccine**     **Manufacturer**           **Serogroups**   **Protein conjugate**
  --------------- -------------------------- ---------------- ---------------------------------------------------
  Menveo^™^       Novartis Vaccines          A, C, Y, W-135   Diphtheria cross-reactive material 197 (CRM~197~)
  Menactra^™^     Sanofi Pasteur             A, C, Y, W-135   Diphtheria toxoid
  Meningitec^™^   Wyeth Vaccines             C                CRM~197~
  Menjugate^®^    Novartis Vaccines          C                CRM~197~
  NeisVac-C^™^    Baxter Bioscience          C                Tetanus toxoid
  MenAfriVac^™^   Serum Institute of India   A                Tetanus toxoid

Adapted with permission from Vaccines, 5th ed, Granoff et al, Meningococcal Vaccines, p 399--434, Copyright Elsevier (2008).[@b93-idr-4-161]

###### 

Global meningococcal conjugate vaccine programs

  **Country**                                                                                                           **Vaccine product**                                      **Year introduced**   **Schedule**
  --------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- --------------------- ------------------------------------------------------------------------------------------------------------
  UK[@b94-idr-4-161]                                                                                                    Men C Conjugate (MenC)                                   1999                  Routine primary series at 3 and 4 mo with booster at 12 mo[^1^](#tfn3-idr-4-161){ref-type="table-fn"}
  Canada[@b95-idr-4-161]                                                                                                Men C                                                    2002                  Single dose at 12 mo (most provinces) with catch up through age 20 yrs
  Men ACYW~d~[^2^](#tfn4-idr-4-161){ref-type="table-fn"} (PEI and NB only)[^4^](#tfn6-idr-4-161){ref-type="table-fn"}   2006                                                                           
  Australia                                                                                                             Men C                                                    2003                  Single dose at 12 mo
  USA                                                                                                                   Men ACWY~d~[^2^](#tfn4-idr-4-161){ref-type="table-fn"}   2005                  Single dose at age 11--18 years; booster dose in 5 years; from age 2 years in certain high risk groups
  Men ACWY~crm~[^3^](#tfn5-idr-4-161){ref-type="table-fn"}                                                              2010                                                                           
  Spain[@b85-idr-4-161]                                                                                                 Men C                                                    2000                  Routine primary series at 2, 4, and 6 mo with catch up through age 6 yrs (3 provinces through adolescence)
  Ireland[@b96-idr-4-161]                                                                                               Men C                                                    2000                  Routine primary series at 4 and 6 mo with booster at 12 mo
  Netherlands[@b79-idr-4-161]                                                                                           Men C                                                    2002                  1 dose at 14 mo
  Belgium[@b97-idr-4-161]                                                                                               Men C                                                    2002                  1 dose at 12 mo
  Germany[@b97-idr-4-161]                                                                                               Men C                                                    2006                  1 dose 12--23 mo
  Greece[@b75-idr-4-161]                                                                                                Men C                                                    2001                  Single dose at 12 mo[^5^](#tfn7-idr-4-161){ref-type="table-fn"}
  Africa (Burkina, Mali, Niger)                                                                                         Men A                                                    2010                  Mass vaccination of 1- to 29-year-olds with single dose

**Notes:**

2, 4, 6 months 1999--2006;

Men A, C, Y, W-135 conjugated to diphtheria toxoid;

Men A, C, Y, W-135 conjugated to diphtheria cross-reactive material 197;

Prince Edward Island; New Brunswick;

Voluntary participation by providers; may be given up to 14 years.

**Abbreviation:** mo, months.
